title: [Treatment of presumed tuberculous uveitis affecting the posterior segment: diagnostic confirmation and long term outcomes].
abstract: OBJECTIVE
  To determine the level of agreement with the presumed diagnosis and long term clinical outcomes after antituberculous therapy (ATT) in a group of patients with presumed tuberculous uveitis (PTU) affecting the posterior segment.
  
  
  METHODS
  Retrospective case series.
  
  
  RESULTS
  A total of 17 patients with chronic refractory or newly diagnosed uveitis affecting the posterior segment were included. All included patients were diagnosed with PTU and received ATT. Median follow-up after ATT was 34 months (range 2-60). Complete control of inflammation was observed in 14/17 patients (82.3%) during the treatment period, and only 4/17 patients (23.5%) had a uveitis relapse over the entire follow-up period after ATT. All patients who had uveitis relapses (4/4), but none from the remaining group (0/13), required immunosuppressive therapy of some kind after ATT. The response to ATT was able to confirm diagnosis of PTU in 14/17 (82.3%) included patients.
  
  
  CONCLUSIONS
  When a clinical suspicion of PTU affecting the posterior segment exists, ATT may be highly effective for both confirming the diagnosis and resolving the inflammatory process. Thus, ATT may offer additional advantages, such as preventing latent-tuberculosis reactivations due to immunosuppressive therapy, and decreasing the number and/or severity of uveitis relapses in some patients. Prospective, randomized studies including a larger number of patients are required to support these and other potential advantages of ATT in such patients.
authors.affiliation: Servicio de Oftalmología, Complejo Asistencial Universitario de León, León, España. miguelcorderocoma@gmail.com
authors.forename: M
authors.initials: M
authors.lastname: Cordero-Coma
authors.forename: I
authors.initials: I
authors.lastname: Garzo
authors.forename: R
authors.initials: R
authors.lastname: Salazar
authors.forename: M
authors.initials: M
authors.lastname: Franco
authors.forename: S
authors.initials: S
authors.lastname: Calleja
authors.forename: J M
authors.initials: JM
authors.lastname: Ruiz de Morales
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000995:Antitubercular Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000009:adverse effects; D007538:Isoniazid / Q000627:therapeutic use; D015864:Panuveitis / Q000175:diagnosis / Q000188:drug therapy; D011718:Pyrazinamide / Q000627:therapeutic use; D012008:Recurrence; D012074:Remission Induction; D012189:Retrospective Studies; D012293:Rifampin / Q000627:therapeutic use; D016896:Treatment Outcome; D014392:Tuberculosis, Ocular / Q000175:diagnosis / Q000188:drug therapy*; D015866:Uveitis, Posterior / Q000175:diagnosis / Q000188:drug therapy*
chemical_list: D000900:Anti-Bacterial Agents; D000995:Antitubercular Agents; D007166:Immunosuppressive Agents; D011718:Pyrazinamide; D007538:Isoniazid; D012293:Rifampin
keywords: Coroiditis serpinginosa; Presumed tuberculous uveitis; Quantiferon; Serpiginous choroiditis; Tuberculosis; Uveitis; Uveítis; Uveítis tuberculosas presuntas